Research Analysts’ Weekly Ratings Changes for CAMP4 Therapeutics (CAMP)

A number of firms have modified their ratings and price targets on shares of CAMP4 Therapeutics (NASDAQ: CAMP) recently:

  • 8/17/2026 – CAMP4 Therapeutics was upgraded by Zacks Research from “strong sell” to “hold”.
  • 8/14/2026 – CAMP4 Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
  • 8/14/2026 – CAMP4 Therapeutics was given a new $15.00 price target by UBS Group AG.
  • 8/14/2026 – CAMP4 Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $15.00 price target on the stock, up from $12.00.
  • 7/15/2026 – CAMP4 Therapeutics was downgraded by Zacks Research from “hold” to “strong sell”.

Insiders Place Their Bets

In other news, Director Andrew J. Schwab sold 32,018 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $4.50, for a total value of $144,081.00. Following the completion of the sale, the director owned 2,433,280 shares of the company’s stock, valued at $10,949,760. This represents a 1.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard A. Young bought 16,378 shares of the stock in a transaction dated Monday, August 3rd. The stock was bought at an average price of $1.65 per share, with a total value of $27,023.70. Following the purchase, the director owned 186,388 shares of the company’s stock, valued at approximately $307,540.20. This represents a 9.63% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have purchased 36,031 shares of company stock valued at $59,451 and have sold 193,603 shares valued at $887,992. 21.69% of the stock is currently owned by corporate insiders.

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.

Featured Stories

Receive News & Ratings for CAMP4 Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAMP4 Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.